The Impact of Pharmaceutical Care Intervention on Medication Compliance and Efficacy in Hypertension Patients of Bai Ethnic Minority

Abstract

Abstract:

Objective： To investigate the impact of pharmaceutical care intervention on medication compliance and efficacy in hypertension patients of Bai ethnic minority. Methods： A total of 106 essential hypertension patients of Bai ethnic minority who were treated in the First Affiliated Hospital of Dali University from January to June 2020 were selected as study objects， and randomly divided into control group and intervention group. The control group received routine pharmaceutical care， and the intervention group adopted the plan-do-check-action（PDCA） cycle to carry out pharmaceutical care. The quality of life scores， blood pressure control， medication compliance and incidence of adverse reactions were compared before and after intervention in both groups. Results： After intervention， the scores of each dimension in the quality of life scale in the intervention group were significantly higher than those in the control group， and the systolic and diastolic blood pressure were significantly lower than those in the control group， with statistical significance（P<0.01）； the medication compliance rate in the intervention group was significantly higher than that in the control group， and the incidence of adverse drug reactions was significantly lower than that in the control group， with statistical significance（P<0.01）. Conclusion： Adopting PDCA cycle to carry out pharmaceutical care can improve medication compliance of hypertension patients of Bai ethnic minority and help them better control blood pressure.

Key words:

pharmaceutical care intervention, Bai ethnic minority, hypertension, medication compliance

CLC Number:

R544.1 ','1');return false;" target="_blank">
R544.1

Li Xia , Dong Xiaowei, Qiu Lin, Yang Pihui, Dong Ying, Wang Qinggui, Gu Yun.

The Impact of Pharmaceutical Care Intervention on Medication Compliance and Efficacy in Hypertension Patients of Bai Ethnic Minority [J]. Journal of Dali University, 2023, 8(10): 16-20.

References

〔1〕国家心血管病中心.中国心血管病报告2016〔M〕.北京：中国大百科全书出版社，2017.

〔2〕蒋立新，路甲鹏，李希.China PEACE 170万名成人的数据：高血压患病、知晓、治疗和控制情况〔J〕.中华内科杂志，2018，57（1）：62.

〔3〕大理白族自治州统计局.大理白族自治州2021年国民经济和社会发展统计公报〔EB/OL〕.（2022-02-14）〔2022-08-03〕.http：//yndali.gov.cn/dlrmzf/c100640/202202/708c31

d0937541b89ff62a54c0372c56.shtml.

〔4〕李利华，姚超永，李雪艳，等.大理地区高血压患病率调查及影响因素分析〔J〕.中国全科医学，2011，14（15）：1687-1689.

〔5〕董玲，彭云珠，黄橙，等.云南大理白族高血压患病率及相关危险因素流行病学调查〔J〕.昆明医科大学学报，2018，39（7）：52-57.

〔6〕国家卫生计生委合理用药专家委员会，中国医师协会高血压专业委员会.高血压合理用药指南（第2版）〔J〕. 中国医学前沿杂志（电子版）， 2017，9（7）： 28-126.

〔7〕中华医学会，中国医学杂志社，中华医学会全科医学分会，等.高血压基层诊疗指南（2019年）〔J〕. 中华全科医师杂志， 2019，18（4）： 301-313.

〔8〕中国高血压防治指南修订委员会，高血压联盟（中国），中华医学会心血管病学分会，等.中国高血压防治指南（2018年修订版）〔J〕. 中国心血管杂志， 2019， 24（1）： 24-56.

〔9〕李会敏，苏长龙，秘子涵，等. 大庆市龙凤社区居民高血压患病率、知晓率、治疗率、控制率及患病影响因素分析〔J〕. 中国公共卫生， 2017， 33（3）： 396-400.

〔10〕漆莉. 重庆市社区糖尿病干预现状及新型模式研究〔D〕. 重庆：第三军医大学， 2016.

〔11〕孙倩，井明霞，王奎，等.老年高血压患者服药依从性自我报告两种常用问卷适用性分析〔J〕.中国公共卫生，2020，36（7）：990-993.

〔12〕 JARACHOVIC M，MASON M，KERBER K，et al. The Role of Standardized Protocols in Unplanned Extubations in a Medical Intensive Care Unit〔J〕.Am J Crit Care，2011，20（4）： 304-311.

〔13〕 TAO L S，HART P，EDWARDS E， et al. Treatment of Difficult-to-Control Blood Pressure in a Multidisciplinary Clinic at a Public Hospital〔J〕. J Natl Med Assoc， 2003， 95（4）：263-269.

〔14〕 PHILLIPS S L，CARR-LOPEZ S M. Impact of Pharmacist on Medication Discontinuation in a Hospital-Based Geriatric Clinic〔J〕. Am J Hosp Pharm，1990，47（5）：1075-1079.

〔15〕李晶.药学服务干预对社区老年高血压患者血压控制及用药依从性的影响〔J〕．中外女性健康研究，2018（24）：118.

〔16〕黄睿祺.加强药学干预对高血压患者血压控制及用药依从性的影响探讨〔J〕．中国现代药物应用，2018，12（19）：134-135.

〔17〕健康中国行动推进委员会.健康中国行动（2019—2030年）〔EB/OL〕．（2019-07-09）〔2022-09-07〕.http：//www.nhc.gov.cn/guihuaxxs/s3585u/201907/e9275fb95d5b4295be8308415d4cd1b2.shtml.